GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cytokinetics CYTK · USD

Health Care · US listing · 🇺🇸 United States

Compare

55.14

+2.70%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$88.0m

FY2016FY2025

Net income

−$785.0m

FY2016FY2025

Free cash flow

−$534.8m

FY2016FY2025

Shareholders' equity

−$659.6m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$88.0m$18.5m$7.5m$94.6m$70.4m$55.8m$26.9m$31.5m$13.4m$106.4m
Gross profit$77.9m−$320.9m−$322.6m−$146.2m−$89.5m−$41.1m−$59.3m−$57.6m−$76.9m$46.5m
Research and development$405.9m$339.4m$330.1m$240.8m$159.9m$97.0m$86.1m$89.1m$90.3m$59.9m
Operating income−$729.5m−$554.5m−$495.3m−$349.1m−$186.3m−$93.9m−$98.9m−$88.9m−$113.4m$18.7m
Net income−$785.0m−$589.5m−$526.2m−$389.0m−$215.3m−$127.3m−$121.7m−$106.3m−$127.8m$16.5m
Diluted earnings per share-6.41-4.99-5.31-4.11-2.56-1.80-2.05-1.94-2.370.38

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$1.42bn$1.40bn$824.3m$1.01bn$841.3m$533.8m$289.8m$211.2m$294.8m$170.1m
Cash and short-term investments$882.2m$1.08bn$614.8m$782.6m$471.6m$464.1m$225.1m$198.7m$268.9m$156.2m
Total liabilities$2.08bn$1.54bn$1.21bn$1.12bn$597.5m$420.4m$300.8m$185.2m$185.0m$75.8m
Debt$1.18bn$657.1m$618.6m$611.6m$144.1m$135.7m$129.3m$42.4m$31.8m$29.9m
Shareholders' equity−$659.6m−$135.4m−$386.3m−$107.9m$243.9m$113.4m−$10.9m$25.9m$109.8m$94.4m
Shares outstanding122m118m99m95m84m71m59m55m54m44m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$510.0m−$395.9m−$414.3m−$299.5m−$142.5m$8.9m−$90.9m−$101.2m−$101.8m$37.0m
Capital spending−$24.8m−$3.9m−$1.4m−$11.3m−$48.9m−$11.1m−$2.6m−$889,000−$2.9m−$1.6m
Free cash flow−$534.8m−$399.8m−$415.7m−$310.9m−$191.4m−$2.1m−$93.5m−$102.1m−$104.6m$35.4m
Dividends paid——−$18.5m———————

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$31.9m$19.4m$17.8m$1.9m$66.8m$1.6m$16.9m$463,000
Gross profit$29.2m$17.0m$14.9m−$743,000$64.5m−$98.3m−$76.7m−$84.1m
Operating income−$177.9m−$183.7m−$183.0m−$279.9m−$110.1m−$152.1m−$142.4m−$155.3m
Net income−$198.8m−$206.0m−$183.0m−$306.2m−$134.4m−$161.4m−$150.0m−$160.5m
Diluted earnings per share-1.50-1.56-1.49-2.50-1.10-1.32-1.27-1.36
Cash from operations−$159.0m−$145.0m−$142.0m−$107.0m−$128.0m−$131.0m−$65.0m−$101.0m
Capital spending−$4.0m−$5.0m−$5.0m−$9.0m−$4.0m−$5.0m−$1.0m−$2.0m
Free cash flow−$163.0m−$150.0m−$147.0m−$116.0m−$132.0m−$136.0m−$66.0m−$103.0m
Total assets$1.92bn$1.27bn$1.42bn$1.44bn$1.23bn$1.26bn$1.40bn$1.44bn
Cash and short-term investments$1.17bn$818.5m$882.2m$962.5m$858.1m$938.2m$1.08bn$1.01bn
Debt$1.17bn$1.18bn$1.18bn$1.09bn$747.0m$677.7m$676.1m$674.9m
Shareholders' equity−$173.5m−$826.6m−$659.6m−$521.1m−$368.7m−$266.4m−$135.4m−$13.9m

Financial ratios

Data as of 8 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin88.5%-1737.2%-4284.1%-154.6%-127.1%-73.7%
Operating margin-891.6%-2722.8%-6222.8%-357.1%-264.1%-158.7%
Net margin-891.6%-3191.1%-6988.6%-411.2%-305.7%-228.0%
Return on equity119.0%435.5%136.2%360.5%-88.3%-112.3%
Return on assets-55.1%-42.1%-63.8%-38.3%-25.6%-23.8%
Free cash flow yield-6.5%-5.4%-6.8%-5.0%-1.8%0.5%
Revenue growth376.6%145.3%-92.0%34.3%26.2%107.8%
Earnings growth33.2%12.0%35.3%80.6%69.2%4.6%
Current ratio4.53x6.17x6.12x9.40x7.45x15.20x
Debt to equity-1.78x-4.99x-1.64x-0.72x0.26x0.43x
Equity ratio-46.3%-9.7%-46.9%-10.6%29.0%21.2%
Interest coverage-7.56x-5.81x-8.13x-6.60x-6.34x-2.29x
R&D as a share of sales461.0%1837.2%4384.1%254.6%227.1%173.7%
Buybacks as a share of market value-3.7%-19.2%-4.6%-12.6%-18.7%-19.5%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-2.4%9.5%11.9%
Operating income27.8%50.7%34.6%
Net income26.4%43.9%35.5%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin-228.2%-341.2%-251.6%-186.0%
Operating margin-1205.5%-1020.2%-719.3%-503.7%
Net margin-1290.4%-1097.5%-786.0%-555.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-9.9-9.4-15.7-11.2-17.8-11.6-3.0-1.9-2.018.7
Price to sales88.4300.6—45.954.426.413.56.319.02.9

Market value over time

31 Oct 2016 to 7 Oct 2026, in USD

$417.1m$8.07bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return34%26%-16%11%93%237%68%-25%-31%21%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 6-to-1 reverse split · 25 Jun 2013

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.